Climb Bio to present preliminary Phase 2 PrisMN trial data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026

Bitget2026/10/02 13:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Climb Bio flagged new clinical updates for CLYM116 and budoprutug ahead of ASN Kidney Week 2026 in Denver on Oct. 21-25.
Preliminary Phase 2 results from the PrisMN study of budoprutug in primary membranous nephropathy will be presented on Oct. 24.
The readout is positioned as an early look at safety and efficacy, marking a key milestone for the CD19 antibody program.
Phase 1 data for CLYM116 in healthy volunteers will be presented on Oct. 22-23, supporting development in IgA nephropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020930PRIMZONEFULLFEED9838696) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Climb Bio to present preliminary Phase 2 PrisMN trial data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026

You may also like

Crypto prices